Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include ...

Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as $60 ...

Two former Pfizer executives drawn into a campaign by activist investor Starboard Value to shake up the company have withdrawn their support for the plan. Pfizer's ex-chair and chief executive Ian ...

Pfizer’s buyout of Seagen was among the issues Starboard Value pointed to in October of last year when it called on the company’s board to “hold management accountable” for what it ...

Despite facing legal challenges and investor pressure, such as litigation related to Oxbryta and interactions with activist investor Starboard, Pfizer has remained resilient. Its strategic ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the new Donald Trump administration. Health care stocks can often be a solid defensive play in an uncertain economy.

Starboard’s Kenvue saga came shortly after it picked up a $1 billion stake in Pfizer and initiated a proxy fight with the New York-based drugmaker. However, after criticizing the company’s R&D ...

Chewy Inc.'s stock rose 4.9% early Tuesday after the online pet-product retailer blew past earnings estimates for the fourth quarter, buoyed by strong customer growth. The activist investor is trying ...

Pfizer's latest plot twist includes an expanded European nod for its RSV vaccine, ABRYSVO, and a new autoimmune collab with ...